Request a Rep
Request a Rep
CAMZYOS is Now Included in the 2024 AHA/ACC/Multisociety HCM Guideline See the updated Guidelines >

CAMZYOS is Now Included in the 2024 AHA/ACC/Multisociety HCM Guideline

See the updated Guidelines >

Redefining the Treatment Landscape for Symptomatic
NYHA Class II–III Obstructive HCM1,2

CAMZYOS® is the first and only approved cardiac myosin inhibitor that targets HCM at the source.1,2

CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state.
This reduces the number of myosin-actin cross-bridges that form.1

The Body of Evidence for CAMZYOS Continues to Expand with 2 Phase 3 Trials and their Ongoing Long-Term Extensions (LTE)1-4
Checklist and Shield Icon

Starting patients on CAMZYOS

Access to everything you need to start
appropriate patients on CAMZYOS.

Magnifying Glass Icon


Locate REMS-certified healthcare providers with CAMZYOS treatment experience

Monitor Icon

CAMZYOS Resources

Find information about patient support, program details,
enrollment information, and downloadable resources.

HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; REMS=Risk Evaluation and Mitigation Strategy.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.


  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X
  3. Garcia-Pavia P, Oreziak A, Masri A, et al. Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks. Presented at ESC 2023. Oral presentation 835382.
  4. Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8(10):968-977.